1-3 of 3
Hanjing Xie
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Trial in Progress: An Open-Label, Multi-Center, First in Human, Phase 1/2a Trial to Evaluate the Safety and Preliminary Efficacy of Autologous Tolerogenic Dendritic Cells Ex Vivo Loaded with Recombinant Factor VIII (FVIII) in Adults with Congenital Hemophilia a (HA) with Neutralizing Antibodies to FVIII and Having Failed Immune Tolerance Induction (ITI)

Jan Astermark, Rolf Ljung, Eva Karlsson, Hanjing Xie
Journal: Blood
Blood (2022) 140 (Supplement 1): 12733–12734.
https://doi.org/10.1182/blood-2022-157250
Published: 2022
Journal Articles

PORT (OP-109): Phase 2, Randomized, Pharmacokinetic (PK), Cross-over Study of Peripheral Vs Central Intravenous Administration of Melflufen in Patients with Relapsed/Refractory Multiple Myeloma (RRMM)

Jiri Minarik, Ilina Micheva, Ganna Usenko, Gabor Mikala, Kameliya Simeonova, Marcus Thuresson, Markus Jerling, Hanjing Xie, Ludek Pour
Journal: Blood
Blood (2021) 138 (Supplement 1): 4772.
https://doi.org/10.1182/blood-2021-150639
Published: 2021
Journal Articles

Quantitative Pharmacogenetics of Cyclophosphamide in Patients with Hematological Malignancies.

Moustapha Hassan, PhD, Hanjing Xie, PhD, Lars Ståhle, PhD, Zuzana Hassan, MD PhD, Eva Kimby, MD PhD
Journal: Blood
Blood (2004) 104 (11): 4604.
https://doi.org/10.1182/blood.V104.11.4604.4604
Published: 2004